Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy

다국어 초록 (Multilingual Abstract)

Purpose: This study was performed to assess the reliability and validity of the Korean version of European Organization for Research andTreatment of Cancer Quality of Life Questionnaire - Chemotherapy-induced peripheral neuropathy 20 items (EORTC QLQ-CIPN20) in patientsreceiving neurotoxic chemotherapy. Methods: A convenience sample of 249 Korean cancer patients, previously or currently, beingtreated with peripheral neurotoxic chemotherapeutic agents were asked to fill in the questionnaire. Collected data were analyzed usingSPSS 21.0 and AMOS 21.0. Construct validity, known-group validity, concurrent validity, and internal consistency reliability of the Koreanversion of the QLQ-CIPN20 were evaluated. Results: Factor analysis confirmed 3 dimensions of CIPN: sensory, motor, and autonomic.
The factor loadings of the 20 items on the 3 subscales ranged from .38 to .85. The 3 subscale-model was validated by confirmatory factoranalysis (GFI=.90, AGFI=.86, RMSR=.05, NFI=.87, and CFI=.94), and concurrent validity was demonstrated with the EORTC QLQC30.
Furthermore, the QLQ-CIPN20 established known-group validity. The Cronbach’s alpha coefficients for internal consistency of thesubscales ranged from .73 to .89. Conclusion: The Korean version of the EORTC QLQ-CIPN20 showed satisfactory construct, concurrent,and known-group validity, as well as internal reliability.

참고문헌 (Reference)

1 곽미경(Kwak, Mi Kyong), "항암화학요법으로 인한 암환자의 말초신경병증 관련 특성과 삶의 질" 대한종양간호학회 10 (10): 231-239, 2010

2 김정혜, "항암화학요법으로 인한 말초신경병증을 경험하는 대장암 환자의 삶의 질" 대한종양간호학회 11 (11): 254-262, 2011

3 이은현, "추후관리 받는 암환자의 요구 측정도구 개발 및 평가" 한국간호과학회 40 (40): 551-560, 2010

4 김혜영, "유방암 환자의 항암화학요법으로 인한 말초신경병증과 삶의 질" 대한종양간호학회 13 (13): 222-230, 2013

5 김은주, "노인의 성공적 노화 측정도구에 대한 요인 구성타당도 평가" 한국간호과학회 43 (43): 568-577, 2013

6 Yun YH, "Validation of the Korean version of the EORTC QLQ-C30" 13 (13): 863-868, 2004

7 Tabachnick BG, "Using multivariate statistics" Harper Collins Publishers 1996

8 Delforge M, "Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues" 11 (11): 1086-1095, 2010

9 Oken MM, "Toxicity and response criteria of the eastern cooperative oncology group" 5 (5): 649-655, 1982

10 Postma TJ, "The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20" 41 (41): 1135-1139, 2005

11 Cavaletti G, "The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings" 24 (24): 454-462, 2013

12 Aaronson NK, "The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology" 85 (85): 365-376, 1993

13 Fayers PM, "The EORTC QLQ-C30 scoring manual"

14 Visovsky C, "Putting evidence into practice: Evidence-based interventions for chemotherapyinduced peripheral neuropathy" 11 (11): 901-913, 2007

15 Nunnally JC, "Psychometric theory" McGraw-Hill 1994

16 Seon Ha Kim, "Psychometric Properties of the Korean Short Form-36 Health Survey Version 2 for Assessing the General Population" 한국간호과학회 7 (7): 61-66, 2013

17 Park HA, "Problems and issues in developing measurement scales in nursing" 14 (14): 46-72, 2005

18 Kiser DW, "Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments" 37 (37): 758-764, 2010

19 Tofthagen C, "Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin" 15 (15): 182-188, 2011

20 Azhary H, "Peripheral neuropathy : Differential diagnosis and management" 81 (81): 887-892, 2010

21 Griffith KA, "Measures of chemotherapy- induced peripheral neuropathy: A systematic review of psychometric properties" 15 (15): 314-325, 2010

22 Postma TJ, "Grading of chemotherapy-induced peripheral neuropathy" 11 (11): 509-513, 2000

23 Richardson PG, "Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib" 24 (24): 3113-3120, 2006

24 Dewolf L, "EORTC quality of life group translation procedure" EORTC Quality of Life Group 2009

25 Wickham R, "Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice" 11 (11): 361-376, 2007

26 Dunlap B, "Chemotherapy-induced peripheral neuropathy : A need for standardization in measurement" 4 (4): 398-399, 2006

27 Mols F, "Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry" 31 (31): 2699-2707, 2013

28 Kautio AL, "Burden of chemotherapy-induced neuropathy-a cross-sectional study" 19 (19): 1991-1996, 2011

29 Kim GS, "Analysis structural equation modeling" Hannarae Publishing Co 2007

30 Barton DL, "A double-blind, placebo-controlled trial of a topical treatment for chemotherapy- induced peripheral neuropathy: NCCTG trial N06CA" 19 (19): 833-841, 2011